

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	"6429311".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/05 12:38
S2	20	("5798344" "6331541" "6444686" "6492400" "6521592" "6525069" "6605623" "6780857" "6875776" "6897234" "6906066" "6919368").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/31 12:15
S3	783	quinazolinone.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:07
S4	344	hansch.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:40
S5	0	hansch.in. and qsar	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:40
S6	0	hansch.in. and structure adj activity	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:41
S7	0	hansch.in. and pharma\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:41

EAST Search History

S8	0	hansch-\$.in. and pharma\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S9	342	hansch-\$.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S10	0	hansch-\$.in. and drug	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S11	2	dihydro adj quinazolinone.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:07
S12	6	quinazolinone.ab. and prostaglandin	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:16
S13	165	quinazolinone and prostaglandin	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:16
S14	159	quinazolinone and prostaglandin not S12	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:25

EAST Search History

S15	2	"6759410".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:25
S16	5	"3375250".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/05 12:29
S17	3	"3843654".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/05 12:29
S18	3	"3843654".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/05 16:17

== FILE CAPLUS

FILE 'CAPLUS' ENTERED AT 10:29:16 ON 25 MAY 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23
 FILE LAST UPDATED: 24 May 2007 (20070524/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

== D QUE L11
 L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
 Uploading strA.str



Page 1 of 27

== D IBIS ED ABS HITSTR L11 1

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:308434 CAPLUS Full-text

DOCUMENT NUMBER: 140:339338

TITLE: Preparation of quinazolin-4-one derivatives as PGD2 synthetase inhibitors

INVENTOR(S): Itai, Akiko; Muto, Susumu;

Inoue, Toshiyoshi; Uraide, Yoshihiro

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXX22

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031180	A1	20040415	WO 2003-JP12648	20031002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, ML, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TO				
CA 2503674	A1	20040415	CA 2003-2503674	20031002
AU 2003268735	A1	20040423	AU 2003-268735	20031002
GB 2410025	A	20050720	GB 2005-7682	20031002
GB 2410025	B	20070328		
US 2006229324	A1	20061012	US 2005-529946	20051004
PRIORITY APPLN. INFO.:			JP 2002-291114	A 20021003
			WO 2003-JP12648	W 20031002


OTHER SOURCE(S): MARPAT 140:339338

ED Entered STN: 15 Apr 2004

OI



I



II

AB The title compds. I [wherein X = (un)substituted N=CH or NHCH2; R1-R4 = independently H, halo, (un)substituted alkyl, or OR; R = (un)substituted NH2] or pharmaceutically acceptable salts, hydrates, or solvates thereof are

Page 3 of 27

chain nodes :

11 12 15 16 17 23 24 25 26 27 28 29 30 31 32 33 34 35 42 43 44
 58 59 66 67

ring nodes :

1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 36 37 38 39 40 41 45 46
 47 48 49 50 51 52 53 54 55 56 57

chain bonds :

7-11 8-66 9-15 16-17 17-18 23-24 24-25 25-26 25-27 26-29 29-30 30-31

31-32 31-33 34-35 35-36 39-42 42-43 42-44 45-58 51-67 58-59

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 18-19 18-22 19-20 20-21

21-22 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-50 46-47 47-48 48-49

48-51 49-50

49-53 51-52 52-53 52-54 53-57 54-55 55-56 56-57

exact/norm bonds :

4-7 5-10 7-8 7-11 8-9 8-66 9-10 9-15 16-17 18-19 18-22 19-20 20-21 21-22

23-24 28-29 34-35 39-42 48-51 49-53 51-52 51-67 58-59

exact bonds :

17-18 24-25 25-26 25-27 29-30 30-31 31-32 31-33 35-36 42-43 42-44 45-58

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-50

46-47 47-48 48-49 49-50 52-53 52-54 53-57 54-55 55-56 56-57

G1: Ak. [*1]

G2: [*2], [*3], [*4], [*5], [*6]

Match level :

1: Atom 2: Atom 3: Atom 4: Atom 5: Atom 6: Atom 7: Atom 8: Atom 9: Atom 10: Atom

11: CLASS 12: Atom 13: CLASS 14: CLASS 15: CLASS 16: CLASS 17: CLASS 18: Atom 19: Atom 20: Atom 21: Atom

22: Atom 23: CLASS

24: CLASS 25: CLASS 26: CLASS 27: CLASS 28: CLASS 29: CLASS 30: CLASS 31: CLASS

32: CLASS 33: CLASS

34: CLASS 35: CLASS 36: Atom 37: Atom 38: Atom 39: Atom 40: Atom 41: Atom 42: CLASS

43: CLASS

44: CLASS 45: Atom 46: Atom 47: Atom 48: Atom 49: Atom 50: Atom 51: Atom 52: Atom

53: Atom 54: Atom

55: Atom 56: Atom 57: Atom 58: CLASS 59: CLASS 66: CLASS 67: CLASS

Generic attributes :

12:

Saturation : Unsaturated

67:

Number of Carbon Atoms : less than 7

L5 86 SEA FILE-REGISTRY SSS FUL L3
 L6 4 SEA FILE-CAPLUS ABS-ON PLU-ON L5
 L7 266 SEA FILE-CAPLUS ABS-ON PLU-ON ITAI A7/AU
 L8 1390 SEA FILE-CAPLUS ABS-ON PLU-ON MUTO S7/AU
 L9 11982 SEA FILE-CAPLUS ABS-ON PLU-ON INOUE T7/AU
 L10 262 SEA FILE-CAPLUS ABS-ON PLU-ON URAIDE Y7/AU
 L11 1 SEA FILE-CAPLUS ABS-ON PLU-ON (L7 OR L8 OR L9 OR L10) AND L6

Page 2 of 27

prepared as prostaglandin D2 synthase (PGD2) inhibitors. For example, the compound II was prepared in a four-step synthesis. Compds. I showed strong inhibitory effect against human PGD2.


IT

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USRS (Uses)

(drug candidate; preparation of quinazolinone derivate as PGD2 synthetase inhibitors)

RN 679843-64-2 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



IT 679843-65-3P 679843-66-4P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USRS (Uses)


(drug candidate; preparation of quinazolinone derivate as PGD2 synthetase inhibitors)

RN 679843-65-3 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 679843-66-4 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.


Page 4 of 27




IT 679843-30-2P 679843-34-6P 679843-35-7P
679843-37-9P 679843-38-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)
RN 679843-30-2 CAPLUS
CN Acetic acid, [[3-methyl-4-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-34-6 CAPLUS
CN 1H-Pyrazole-3-propanoic acid, 5-hydroxy-4-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-35-7 CAPLUS
CN 1H-Pyrazole-3-propanoic acid, 5-hydroxy-4-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 679843-37-9 CAPLUS
CN 1H-Pyrazole-3-butanonic acid, 5-hydroxy-4-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-38-0 CAPLUS
CN 1H-Pyrazole-3-butanonic acid, 5-hydroxy-4-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)




IT 371120-60-4P 384353-13-3P 384812-90-2P
679843-29-9P 679843-31-3P 679843-32-4P
679843-33-5P 679843-36-8P 679843-39-1P
679843-40-4P 679843-41-5P 679843-42-6P
679843-43-7P 679843-44-8P 679843-45-9P
679843-46-0P 679843-47-1P 679843-48-2P
679843-49-3P 679843-50-6P 679843-51-7P
679843-52-8P 679843-53-9P 679843-54-0P
679843-55-1P 679843-56-2P 679843-57-3P
679843-58-4P 679843-59-5P 679843-60-8P
679843-61-9P 679843-62-0P 679843-63-1P
679843-67-5P 679843-68-6P 679843-69-7P
679843-70-0P 679843-71-1P 679843-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)
RN 371120-60-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 384353-13-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 384812-90-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-29-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-ethoxy-3-methyl-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-31-3 CAPLUS
CN Acetic acid, [[3-methyl-4-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX NAME)


NAME)




RN 679843-32-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[3-ethyl-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-33-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-36-8 CAPLUS
CN 1H-Pyrazole-3-propanamide, 5-hydroxy-4-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 679843-39-1 CAPLUS
CN 1H-Pyrazole-3-butanamide, 5-hydroxy-4-[[[2-methyl-4-oxo-3(4H)-quinazolinyl]imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 679843-40-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-1,3-dimethyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-41-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[1-(2-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-42-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-43-7 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[[1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-44-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-45-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-46-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-ethyl-3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)




RN 679843-47-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-


yl)methylene]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 679843-48-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-butyl-3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)




RN 679843-49-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (9CI) (CA INDEX NAME)




RN 679843-50-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1,1-dimethylethyl)-3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)




RN 679843-51-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(hydroxymethyl)-3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



RN 679843-52-8 CAPLUS
CN Acetic acid, [[4-[[[2-(hydroxymethyl)-4-oxo-3(4H)-quinazolinyl]imino]methyl]-3-methyl-1-phenyl-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 679843-53-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(hydroxymethyl)-3-[[[5-hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)




RN 679843-54-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)







RN 679843-55-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 679843-56-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(3-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 679843-57-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(2-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 679843-62-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-63-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-6,7-dimethoxy-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-67-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(2,2-diphenylethylidene)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-68-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(3,3-diphenyl-2-propenylidene)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-58-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 679843-59-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2,8-dimethyl- (9CI) (CA INDEX NAME)




RN 679843-60-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-61-9 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-[[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-69-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(3-[4-(1,1-dimethylethyl)phenyl]-5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 679843-70-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(5-hydroxy-1-phenyl-3-tricyclo[3.3.1.1.3,7]dec-1-yl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-71-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(4-(diphenylamino)phenyl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-72-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[(9-ethyl-9H-carbazol-3-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=> D QUE L6
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading STRA.STR



chain nodes :
11 12 15 16 17 23 24 25 26 27 28 29 30 31 32 33 34 35 42 43 44
58 59 66 67
ring nodes :
1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 36 37 38 39 40 41 45 46
47 48 49 50 51 52 53 54 55 56 57
chain bonds :
7-11 8-66 9-15 16-17 17-18 23-24 24-25 25-26 25-27 28-29 29-30 30-31
31-32 31-33 34-35 35-36 39-42 42-43 42-44 45-58 51-67 58-59
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 18-19 18-22 19-20 20-21
21-22 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-50 46-47 47-48 48-49
48-51 49-50
49-53 51-52 52-53 52-54 53-57 54-55 55-56 56-57
exact/norm bonds :
4-7 5-10 7-8 7-11 8-9 8-66 9-10 9-15 16-17 18-19 18-22 19-20 20-21 21-22
23-24 28-29 34-35 39-42 48-51 49-53 51-52 51-67 58-59
exact bonds :
17-18 24-25 25-26 25-27 29-30 30-31 31-32 31-33 35-36 42-43 42-44 45-58
normalized bonds :

Page 17 of 27

Page 18 of 27

1-2 1-6 2-3 3-4 4-5 5-6 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-50
46-47 47-48 48-49 49-50 52-53 52-54 53-57 54-55 55-56 56-57

G1: Ak, [*1]
G2: [*2], [*3], [*4], [*5], [*6]


Match level :
1: Atom 2: Atom 3: Atom 4: Atom 5: Atom 6: Atom 7: Atom 8: Atom 9: Atom 10: Atom
11: CLASS 12: Atom 15: CLASS 16: CLASS 17: CLASS 18: Atom 19: Atom 20: Atom 21: Atom
22: Atom 23: CLASS
24: CLASS 25: CLASS 26: CLASS 27: CLASS 28: CLASS 29: CLASS 30: CLASS 31: CLASS
32: CLASS 33: CLASS
34: CLASS 35: CLASS 36: Atom 37: Atom 38: Atom 39: Atom 40: Atom 41: Atom 42: CLASS
43: CLASS
44: CLASS 45: Atom 46: Atom 47: Atom 48: Atom 49: Atom 50: Atom 51: Atom 52: Atom
53: Atom 54: Atom
55: Atom 56: Atom 57: Atom 58: CLASS 59: CLASS 66: CLASS 67: CLASS
Generic attributes :
12:
Saturation : Unsaturated
67:
Number of Carbon Atoms : less than 7

L5 86 SEA FILE=REGISTRY SSS FUL L3
L6 4 SEA FILE=CAPLUS ABB=ON PLU=ON L5

=> S L6 NOT L11
L15 3 L6 NOT L11
=> D IBIB ED ABS HITSTR L15 1-3


L15 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:348325 CAPLUS Full-text
DOCUMENT NUMBER: 129:95463
TITLE: Synthesis and biological activities of some new fully fused quinoxaline derivatives
AUTHOR(S): Ibrahim, S. S.; Abdel-Halim, A. M.; Gabr, Y.; El-Edfawy, S.; Abdel-Rahman, R. M.
CORPORATE SOURCE: Department of Chemistry, Faculty of Education, Ain-Shams University, Cairo, Egypt
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1998), 37B(1), 62-67
CODEN: IJSCDD; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:95463
ED Entered STN: 10 Jun 1998
G1

AB Some fused quinoxaline derivs. have been synthesized via condensation of 3-formylpyrazolo[5,1-b]quinazolin-9(1H)-one with bifunctional reagents followed by ring closure reactions. The structures of the products have been established by their elemental analyses and spectral data (UV, IR, ¹H NMR, mass and X-ray). The antibacterial activity of some products have been also described. I [R = 5-oxo-3-thioxo-hexahydro-1,2,4-triazin-6-yl, CH:CHOC6H4R1-4; R1 = OH, NO2] show a relatively better activity against some tested bacteria than gentamycin.
IT 209746-47-49
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and bactericidal activity of pyrazoloquinazolinone derivs.)
RN 209746-47-4 CAPLUS
CN Pyrazolo[5,1-b]quinazolin-9(4H)-one, 3-[[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:122242 CAPLUS Full-text
DOCUMENT NUMBER: 114:122242
TITLE: Non-steroidal antiinflammatory agents. III: Synthesis of pyrazole derivatives of 4(3H)-quinazolinones
AUTHOR(S): Farghaly, Ahmed M.; Chaaban, Ibrahim; Khalil, Mounir A.; Bekhit, Adnan A.
CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SOURCE: Alexandria Journal of Pharmaceutical Sciences (1990), 4(1), 52-6
CODEN: AJPSER; ISSN: 1110-1792
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:122242
ED Entered STN: 06 Apr 1991
G1




AB Several groups of compds. were synthesized having a pyrazole or pyrazoline moiety attached to 4(3H)-quinazolinone at the 2- or 3-position either directly or through different linkages. The linkages include methinamino, ethenyl, iminomethyl, aminomethyl or methinehydrazino grouping. Thus, acetanthranil (I) was treated with aminoantipyrine II to give 4(3H)-quinazolinone III. The antiinflammatory activity of representative examples of the products is reported.

IT 132088-33-6P 132088-38-1P 132088-39-2P
132088-40-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 132088-33-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 132088-38-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-methyl-3-[[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



RN 132088-39-2 CAPLUS


CN 4(3H)-Quinazolinone, 3-[[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-

Page 21 of 27



RN 132088-40-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 1970:43550 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 72:43550

TITLE: Triazolylbenzoic acids and acylaminoquinazolones from benzoxazinones and carboxylic acid hydrazides

Ried, Walter; Peters, Bert

Org.-Chem. Inst., Univ. Frankfurt, Frankfurt/M., Fed. Rep. Ger.

SOURCE: Justus Liebig's Annalen der Chemie (1969), 729, 124-38

CODEN: JLCBFF; ISSN: 0075-4617

Journal

German

OTHER SOURCE(S): CASREACT 72:43550

ED Entered STN: 12 May 1984

DI For diagram(s), see printed CA issue.

AB 3-(R-substituted)-5-(R1-substituted)-4-(2-carboxyphenyl)-4H-1,2,4-triazoles (I) (R = H, Me or Ph; R1 = Me, CH2CN, CH2NO2, CH2OPh, CH2NHCO2 or Ph) were prepared from 2-(R-substituted)-4H-3,1-benzoxazines and H2NNHCOR1 in boiling EtOH. In hot C6H6, the reaction yielded 2-(R-substituted)-3-(R1OCNH-substituted)-4(3H)-quinazolinone. Both reactions proceeded via 2-R1OCNHHC+RNHC6H4CO2-. 3-Methyl-5-cyanomethyl-4-(2-methylphenyl)-4H-1,2,4-triazole was prepared from 2-MeC6H4N:CMcCl and H2NNHCOCCH2CN. I (R = Me, R1 = CH2CN) boiled in Ac2O gave 5-hydroxy-1-methyl-4-cyano-5-triazolo[4,3-a]quinoline (II).

IT 25380-19-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

Page 22 of 27

(preparation of)

RN 25380-19-2 CAPLUS

CN Pyrazolo[1,5-c]quinazoline-1-carboxamide, 2,3-dihydro-5-methyl-N-(2-methyl-4-oxo-3(4H)-quinazolinyl)- (8CI) (CA INDEX NAME)



=> FILE MARPAT

FILE 'MARPAT' ENTERED AT 10:30:59 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE 'HELP USAGE/TERMS' FOR DETAILS

COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 146 ISS 20 (20070518/BD)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2007078267 05 APR 2007
DE 102005047308 05 APR 2007
EP 1768210 28 MAR 2007
JP 2007082900 05 APR 2007
WO 2007041089 12 APR 2007
GB 2430365 28 MAR 2007
FR 2891276 30 MAR 2007
RU 2296767 10 APR 2007
CA 2556850 24 FEB 2007

Expanded G-group definition display now available.

=> D QUE L14

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L14 1 SEA FILE=MARPAT GSS FUL L3

=> D IBIS AB QHIT 1 L14

L14 ANSWER 1 OF 1 MARPAT COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 140:339318 MARPAT [Full-text](#)

TITLE: Preparation of quinazolin-4-one derivatives as PDZ synthetase inhibitors

INVENTOR(S): Itai, Akiko; Muto, Susumu; Inoue, Tsuyoshi; Urade, Yoshihiro

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031180	A1	20040415	WO 2003-JP12648	20031002
M: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RM: OH, OM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2503674 A1 20040415 CA 2003-2503674 20031002
AU 2003268735 A1 20040423 AU 2003-268735 20031002
GB 2410025 A 20050720 GB 2005-241002 20031002
GB 2410025 B 20070328
US 2006229324 A1 20061012 US 2005-529946 20051004
P 2002-291114 20021003
WO 2003-JP12998 20031002

PRIORITY APPLN. INFO.:

AB The title compds. I [wherein X = (un)substituted N=CH or NHCH2; R1-R4 =
independently H, halo, (un)substituted alkyl, or OH; R = (un)substituted NH2]
or pharmaceutically acceptable salts, hydrates, or solvates thereof are
prepared as prostaglandin D₂ synthase (PGD₂) inhibitors. For example, the
compound II was prepared in a four-step synthesis. Compds. I showed strong
inhibitory effect against human PGD₂.

MSTR 1



G1 = alkyl (containing 1-6 C) (opt. substd.)
G5 = 36



Patent location: claim 1
Note: or pharmaceutically acceptable salts, hydrates or
solvates

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Page 25 of 27

L15 3 SEA ABB=ON PLU=ON L6 NOT L11
=>

=> D HIS NOFILE

(FILE 'HOME' ENTERED AT 09:45:09 ON 25 MAY 2007)

FILE 'CAPLUS' ENTERED AT 09:45:32 ON 25 MAY 2007

L1 E US2005-529946/APPS
1 SEA ABB=ON PLU=ON US2005-529946/APPS
D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 09:46:06 ON 25 MAY 2007

L2 142 SEA ABB=ON PLU=ON (100-07-2/BI OR 100-63-0/BI OR 101498-88-8/
BI OR 1022-46-4/BI OR 105-36-2/BI OR 1073-69-4/BI OR 112351-69-
6/BI OR 118-92-3/BI OR 120107-46-2/BI OR 1210-39-5/BI OR
126592-16-3/BI OR 126592-17-4/BI OR 13024-90-3/BI OR 132871-77-
3/BI OR 134-20-3/BI OR 134017-42-8/BI OR 136304-94-4/BI OR
13811-31-7/BI OR 138625-96-4/BI OR 141-97-9/BI OR 14212-87-4/BI
OR 14580-22-4/BI OR 14763-20-3/BI OR 147778-06-1/BI OR
1710-98-1/BI OR 1711-05-3/BI OR 17364-41-9/BI OR 181185-07-9/BI
OR 18600-55-0/BI OR 1898-06-2/BI OR 1904-60-5/BI OR 19386-06-2
/BI OR 20676-54-4/BI OR 26759-46-6/BI OR 27006-77-5/BI OR
2719-08-6/BI OR 2749-59-9/BI OR 321-07-3/BI OR 3257-39-4/BI OR
3282-30-2/BI OR 3471-32-7/BI OR 371120-60-4/BI OR 38163-38-1/BI
OR 384353-13-3/BI OR 384812-90-2/BI OR 388109-22-6/BI OR
40420-22-2/BI OR 4181-05-9/BI OR 4389-45-1/BI OR 4389-50-8/BI
OR 488100-78-3/BI OR 4949-44-4/BI OR 52173-03-2/BI OR 53904-04-
4/BI OR 55390-99-3/BI OR 57135-06-5/BI OR 5900-58-3/BI OR
60288-17-7/BI OR 60288-19-9/BI OR 60798-06-3/BI OR 63190-57-8/B
I OR 638-29-9/BI OR 6402-09-1/BI OR 658703-33-4/BI OR 66299-68-
1/BI OR 67836-50-4/BI OR 679843-29-9/BI OR 679843-30-2/BI OR
679843-31-3/BI OR 679843-32-4/BI OR 679843-33-5/BI OR 679843-34
-6/BI OR 679843-35-7/BI OR 679843-36-8/BI OR 679843-37-9/BI OR
679843-38-0/BI OR 679843-39-1/BI OR 679843-40-4/BI OR 679843-41
-5/BI OR 679843-42-6/BI OR 679843-43-7/BI OR 679843-44-8/BI OR
679843-45-9/BI OR 679843-46-0/BI OR 679843-47-1/BI OR 679843-48
-2/BI OR 679843-49-3/BI OR 679843-50-6/BI OR 679843-51-7/BI OR
679843-52-8/BI OR 679843-53-9/BI OR 679843-54-0/BI OR 679843-55
-1/BI OR 679843-56-2/BI OR 679843-57-3/BI OR 679843-58-4/BI OR
679843-59-5/BI OR 679843-60-8/BI OR 679843-61-9/BI OR 679843-62
-0/BI OR 679843-63-1/BI OR 679843-64-2/BI OR 679843-65-3/BI OR
679843-66-4/BI

L3 STRUCTURE UPLOADED

L4 4 SEA SSS SAM L3

L5 86 SEA SSS FUL L3

FILE 'CAPLUS' ENTERED AT 10:25:07 ON 25 MAY 2007

L6 4 SEA ABB=ON PLU=ON L5
L7 266 SEA ABB=ON PLU=ON ITAI A7/AU
L8 1390 SEA ABB=ON PLU=ON MUTO S7/AU
L9 11982 SEA ABB=ON PLU=ON INOU E7/AU
L10 262 SEA ABB=ON PLU=ON URADE Y7/AU
L11 1 SEA ABB=ON PLU=ON (L7 OR L8 OR L9 OR L10) AND L6
L12 1 SEA ABB=ON PLU=ON L6 AND P/DT

FILE 'MARPAT' ENTERED AT 10:27:30 ON 25 MAY 2007

L13 0 SEA SSS SAM L3

L14 1 SEA SSS FUL L3

FILE 'CAPLUS' ENTERED AT 10:29:16 ON 25 MAY 2007

Page 26 of 27